

Wholesale Acquisition Cost (WAC) Information for Colorado Prescribers of Prescription Drugs

GEMTESA® (vibegron)

Colorado House Bill 19-1131 requires prescription drug manufacturers to provide the Wholesale Acquisition Cost (WAC) of a prescription drug, in writing, to Colorado prescribers when engaging in prescription drug marketing. This disclosure provides the WAC price for the marketed drug listed below, as well as the names of at least three generic prescription drugs from the same therapeutic class, as available, pursuant to the Colorado requirement.

The WAC pricing information below reflects the published catalog or list prices for the products sold to wholesalers before any discount, rebate, chargeback, or other price reduction and therefore does not represent actual transaction prices. The WAC prices listed may differ significantly from the actual prices paid by patients as most patients do not pay WAC and a patient's out-of-pocket cost will depend on the patient's insurance coverage.

Manufacturer	Marketed Drug	NDC	Dosage Form	Strength	Package Size	WAC
Urovant Sciences, Inc.	GEMTESA®	73336-0075-30	Tablet	75 mg	30	\$472.15
		73336-0075-90	Tablet	75 mg	90	\$1,416.46

Generic Prescription Drugs from the Same Therapeutic Class¹:

None

The pricing information listed does not imply safety or efficacy of the product and is not typically associated with per-dose pricing, price per course of treatment, or the cost effectiveness of the products listed. No comparisons should be made.

GEMTESA® is a trademark of Urovant Sciences GmbH, registered in the U.S. and in other countries.

¹ Colorado House Bill 19-1131 defines "therapeutic class" as "a group of similar drugs that have the same or similar mechanisms of action and are used to treat a specific condition".